Biotechnology Today
more-
Beyond headlines and amyloid, the Alzheimer’s pipeline chugs along
Three therapeutics for Alzheimer’s disease steal the headlines at the moment: Eisai and Biogen’s lecanemab,…
Medtronic’s new MiniMed insulin pump adds 27% boost to time in range, study finds
Vibrant Gastro passes vibrating constipation pill through FDA review
Uncovering a link between lung cancer and chronic pain—and a druggable pathway for both
AnaptysBio’s HARP plays dud note, prompting rethink of imsidolimab strategy
Markets
more-
Weekly Market Review – September 24, 2022
Stock Markets This is the second consecutive week that stocks fell sharply, particularly after the…
Bio Space
more
Novo Nordisk ponies up $1.1B for Forma in effort to shape up sickle cell disease market
Novo Nordisk is handing over $1.1 billion in cash to…
As EU challenge intensifies, Illumina clocks a stateside win in FTC antitrust case over Grail buy
An administrative law judge ruled in Illumina’s favor Thursday in…
Finch axes more than a 3rd of its workforce days after Takeda clips its fiscal wings
A week after taking back two unhatched inflammatory bowel assets…
Global News
more
SpaceX Starlink wins permit to send internet to customers like you
SpaceX has been busy building its Starlink satellite constellation. To…
Facebook video calls soar 1000% during Italy’s lockdown
Facebook has seen usage across its platforms surge in countries…
WeWork board’s special committee is demanding that SoftBank follow through with investment
Five months after SoftBank agreed to a massive bailout of…
Beyond headlines and amyloid, the Alzheimer’s pipeline chugs along
Medtronic’s new MiniMed insulin pump adds 27% boost to time in range, study finds
Vibrant Gastro passes vibrating constipation pill through FDA review
Uncovering a link between lung cancer and chronic pain—and a druggable pathway for both
Novo Nordisk ponies up $1.1B for Forma in effort to shape up sickle cell disease market
As EU challenge intensifies, Illumina clocks a stateside win in FTC antitrust case over Grail buy
Finch axes more than a 3rd of its workforce days after Takeda clips its fiscal wings
Novartis R&D chief Jay Bradner bids adieu to the Swiss Big Pharma
AnaptysBio’s HARP plays dud note, prompting rethink of imsidolimab strategy
As activist investor ratchets up pressure, Mereo makes more cuts to extend cash runway into 2025